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Multiple myeloma remains an incurable disease despite
intensive therapy, including high-dose melphalan and au-
tologous stem cell transplantation (1). Novel treatments
include thalidomide and its derivative lenalidomide and
the proteasome inhibitor bortezomib (1–3).
Bortezomib has been shown to induce apoptosis by
inhibiting activation of nuclear factor kappa B (4). How-
ever bortezomib has also been shown to inhibit angio-
genesis and down-regulate the expression of cell adhesion
molecules (5–7). Furthermore, bortezomib may help to
overcome tumour resistance to corticosteroids or con-
ventional cytotoxic agents, by inhibiting DNA repair
mechanisms (8). The principal mechanism underlying the
anti-tumour activity of thalidomide is uncertain, however
it may be related to its anti-angiogenic and immuno-
modulatory activity, via modulation of TNF alpha, inter-
leukin 10, and interleukin 2 and other cytokines (9).
The addition of corticosteroids such as dexamethasone
has been shown to improve the response rate with bor-
tezomib (10–12). The addition of corticosteroids also
improves the response rate associated with thalidomide
(13–15). However, the added toxicities associated with
the addition of corticosteroids are not insubstantial, the
most serious of which is venous thromboembolism with
one study reporting a rate of 15% for thalido-
mide + dexamethasone vs. 4% for thalidomide alone
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omib and single-agent thalidomide, especially in patients
intolerant to corticosteroids or where the administration
of prophylactic anticoagulants is problematic. Moreover,
a comparison of single-agent bortezomib and single-
agent thalidomide can give an insight into the comparat-
ive biological impact of these two agents.
There have been two recent systematic reviews on the
efﬁcacy of single-agent thalidomide in patients with
relapsed or refractory multiple myeloma (17, 18). The
present study extends these ﬁndings by comparing the
efﬁcacy of thalidomide monotherapy with bortezomib
monotherapy in patients with relapsed or refractory mul-
tiple myeloma.
Methods
Searching strategy
The published English-language literature from 1966 to
June 2005 (MEDLINE, EMBASE, Cochrane library),
publication reference lists, Janssen-Cilag Pty Ltd data-
on-ﬁle and abstracts from recent multiple myeloma con-
ferences were reviewed. Search terms included multiple
myeloma, thalidomide and bortezomib.
Inclusion and exclusion criteria
Studies were included in this analysis if they were pros-
pective, were of patients with relapsed or refractory mul-
tiple myeloma, used single-agent bortezomib or
thalidomide and had at least 30 patients in each treat-
ment arm. Studies were excluded if the treatment added
dexamethasone for non-responders or was short term
(< 3 months) or used ﬁxed doses. The short term and
ﬁxed dose regimens do not correspond to usual clinical
practice and were expected to show poor efﬁcacy for tha-
lidomide. Only bortezomib or thalidomide monotherapy
studies were included in the analysis because of a lack of
combination bortezomib and dexamethasone studies in
the relapsed⁄refractory setting.
Data extraction
Two people independently extracted the data for the tha-
lidomide studies and they resolved any discrepancies by
joint review of the source literature. The data extracted
included summary statistics on the pretreatment charac-
teristics of patients in the studies, as well as efﬁcacy
measures. The primary efﬁcacy measure was response to
treatment. This was measured either as a serum M-pro-
tein reduction of at least 50% or using the European
Group for Blood and Marrow Transplantation (EBMT)
criteria (19). Secondary outcome was complete response
(CR) rate.
Data analysis
The data were analysed on an intent-to-treat basis in
which all patients randomised to the particular treatment
were included. The outcome variables were proportions
that were analysed on an intent-to-treat basis using logis-
tic regression for ﬁxed effects models and the method of
derSimonian and Laird for random effects models (20).
Where possible, the heterogeneity between studies has
been explored and taken into account when assessing the
estimated difference in outcome between treatment with
bortezomib and thalidomide. The random effects esti-
mates were numerically close or identical to the estimates
obtained using the ﬁxed effects models, and therefore
only the ﬁxed effects estimates are reported.
Results
Included studies
Only one study (the APEX study) was identiﬁed where
patients were treated with bortezomib monotherapy (21)
Papers identified in literature 
search (n = 277) 
(n = 0)
Papers excluded from analysis (n = 276): not a clinical trial of 
bortezomib monotherapy in multiple myeloma (n = 57); not 
relapsed or refractory multiple myeloma (n = 4); asymptomatic, 
smouldering or indolent multiple myeloma (n = 0); thalidomide 
used as pre-transplant induction or post-transplant maintenance 
(n = 0); survival or response rate not reported (n = 21); 
dexamethasone added to non-responders (n = 2); sample size <30 
(n = 1); not reflective of clinical practice (n = 0); reviews, 
commentaries or guidelines (n = 191); not published in English 
; duplicates of included studies (n = 0)
Studies included (n = 1)  Figure 1 Flow chart for inclusion and exclusion
of bortezomib studies.
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ded because patients who experienced progressive disease
or did not respond adequately were treated with bortez-
omib plus adjunctive dexamethasone. Thus the APEX
trial was the only bortezomib trial suitable for inclusion
in the systematic review. Where possible, the data ana-
lysed in this report are taken from the ﬁnal study report
addendum (dated 3 August 2005) in which 2-yr follow-
up data were available for the bortezomib arm. In the
APEX trial, 333 patients were randomised to treatment
with bortezomib monotherapy.
Fifteen studies of thalidomide for the treatment of
relapsed or refractory multiple myeloma were consistent
with the inclusion⁄exclusion criteria (Fig. 2). The number
of patients in each trial ranged from 30 to 169 (Table 1).
Patient characteristics
The patients treated with bortezomib in the APEX trial
were similar to those treated in the thalidomide studies
in terms of baseline characteristics (Table 2). However,
in the APEX trial, 48% of patients had prior treatment
with thalidomide, while no patients in the thalidomide
studies had prior treatment with bortezomib.
Response rate
The primary outcome for most studies was response
rate. The best response was available from 14 of the
15 thalidomide studies. However, response to treatment
was not measured consistently between studies. To the
extent possible from the often-limited description of
the response rate criteria, studies with comparable deﬁ-
nitions were compared using either of two criteria: one
based primarily on reduction in serum M-protein
and the other using the EBMT criteria (19). Fortu-
nately, the bortezomib trial was able to furnish both
estimates.
M-protein response rate
The ﬁrst criterion was based on reduction in serum M-
protein by at least 50% from baseline (i.e., those patients
who had a CR or a partial response (PR). For patients
with a low baseline serum M-protein, at least a 90%
reduction in urine M-protein was usually also speciﬁed.
Papers identified in literature 
search (n = 556)
Papers excluded from analysis (n = 541): not a clinical trial of 
thalidomide monotherapy in multiple myeloma (n = 138); not relapsed 
or refractory multiple myeloma (n = 0); asymptomatic, smouldering or 
indolent multiple myeloma (n = 10); thalidomide used as pre-
transplant induction or post-transplant maintenance (n = 11); 
retrospective patient selection (n = 10); survival or response rate not  
reported (n = 15); dexamethasone added to non-responders (n = 3); 
sample size <30 (n = 12); not reflective of clinical practice* (n = 2); 
reviews, commentaries or guidelines (n = 283); not published in 
English (n = 36); duplicates of included studies (n = 21)
Studies included (n = 15)
Figure 2 Flow chart for inclusion and exclusion
of thalidomide studies. *Short-term studies
(<3 months) or studies using ﬁxed doses
regimens were excluded as these do not
correspond to usual clinical practice and were
expected to show poor efﬁcacy.
Table 1 Trials of thalidomide monotherapy in patients with relapsed
or refractory multiple myeloma
Reference Patients treated
Barlogie B et al. (25) 169
Grosbois BB et al. (26) 120
Neben K et al. (27) 83
Yakoub-Agha I et al. (22) 83
Mileshkin L et al. (28) 75
Schey SA et al. (29) 69
Tosi P et al. (30) 65
Waage A et al. (31) 65
Hus M et al. (32) 53
Alexanian RW et al. (33) 45
Hattori Y et al. (34) 44
Cibeira MR et al. (35) 42
Ofﬁdani M et al. (36) 32
Kumar S et al. (37) 32
Richardson P et al. (38) 30
Table 2 Baseline characteristic in the bortezomib study (APEX) and
the thalidomide studies
Baseline patient
characteristic Bortezomib
Thalidomide
Median Range
No. of
studies
Median age, years 62 63 56–69 15
Gender, %male 56 56 44–73 14
IgG : IgA 60 : 23 70 : 16 – 7
b2 microglobulin (mg⁄L) 3.7 3.5 2.9–4.6 6
Disease duration, months 42 44 31–55 9
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determination and the degree of conﬁrmation (e.g., num-
ber of repeat measurements and their timing) for a
potential responder. Although the deﬁnition of M-pro-
tein response varied between studies, the reported
response rates showed little variation between the 10 tha-
lidomide studies that report this outcome (Fig. 3). The
variation in response rates between the thalidomide stud-
ies was not statistically signiﬁcant (v
2 = 13.5, 9 d.f.,
P = 0.14) and the mean response rate was 32% (95%
CI: 29%, 36%).
Most of the variation in response rate between the tha-
lidomide studies reﬂects the high reported response rate
in one study (v
2 = 10.7, 1 d.f., P = 0.002) (22). The des-
cription of the study methods used by Yakoub-Agha does
not explicitly state that conﬁrmation of the reduction in
M-protein was required when assessing a PR (serum M-
protein reduction by at least 50% from baseline).
The M-protein response rate with bortezomib treat-
ment was 53% (95% CI: 47%, 58%). This is higher than
was observed in each of the 10 thalidomide studies and
is statistically signiﬁcantly higher than the mean response
rate for thalidomide (v
2 = 37,1 d.f., P < 0.0001).
Within the APEX trial, the response rate assessed
using M-protein was similar for patients with no prior
exposure to thalidomide (55%, 95⁄172) or with prior
exposure to thalidomide (50%, 80⁄161; v
2 = 1.0, 1 d.f.,
P = 0.3). When the comparison between the 10 thalido-
mide studies and the APEX trial was restricted to
patients without prior exposure to thalidomide, bortez-
omib was still associated with a statistically signiﬁcantly
higher response rate (v
2 = 30, 1 d.f., P < 0.0001).
EBMT response rate
The second response endpoint, reported in four of the
thalidomide studies and in the APEX study, was from
the EBMT criteria. This deﬁnition modiﬁes the M-pro-
tein response to take into account additional clinically
relevant information and results in fewer patients being
classiﬁed as having responded.
The variation in EBMT response rates between the
four thalidomide studies was not statistically signiﬁcant
(v
2 = 2.0, 3 d.f., P = 0.6; Fig. 3) and the mean response
rate was 22% (95% CI: 18%, 28%). The EBMT
response rate with bortezomib treatment was 41% (95%
CI: 35%, 46%). This is higher than was observed in each
of the four thalidomide studies and is statistically signiﬁ-
cantly higher than the mean EMBT response rate for
thalidomide (v
2 = 23.0, 1 d.f., P < 0.0001).
Within the APEX trial, the EBMT response rate was
higher for patients with no prior exposure to thalidomide
(44%, 76⁄172) compared with patients with prior expo-
sure to thalidomide (28%, 45⁄161; v
2 = 9.6, 1 d.f.,
P = 0.002; data from APEX study data ﬁles with last
date of follow-up for response of 14 December 2003).
When the comparison between the four thalidomide
studies and the APEX trial was restricted to patients
without prior exposure to thalidomide, the bortezomib-
thalidomide difference was increased and was still statis-
tically signiﬁcant (v
2 = 23, 1 d.f., P < 0.0001).
One of the thalidomide studies (23) has been omitted
from this analysis because the response rate reported was
the best M-protein response within 60 d of starting treat-
ment with thalidomide. Because some responses will have
occurred after day 60, this measure is not comparable
with those used in the other thalidomide studies. Indeed,
the reported response rate in this study (17%, 20⁄120)
was lower than the M-protein response rates reported in
the other thalidomide studies (Fig. 3). Including the
Strict EBMT criteria
Neben et al., 2002
Mileshkin et al., 2003
Waage et al., 2004
Cibeira et al., 2005
BORTEZOMIB
THALIDOMIDE
0 0.2 0.4 0.6 0.8 1
M-protein ≥50% reduction
Barlogie et al., 2001
Schey et al., 2003
Tosi et al., 2002
Hus et al., 2001
Hattori et al., 2003
Kumar et al., 2003
Offidani et al., 2004
THALIDOMIDE
BORTEZOMIB
0 0.2 0.4 0.6 0.8 1
Richardson et al., 2004
Yakoub-Agha et al., 2002
Alexanian et al., 2000
Figure 3 Response rates for relapsed or refractory multiple myeloma
patients treated with either thalidomide or bortezomib. Response rate
was deﬁned using the EBMT criteria or as a conﬁrmed reduction of at
least 50% in serum M-protein and by at least 90% for urine M-protein
for patients with low baseline serum M-protein.
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duced a biased, low, estimated response rate for treat-
ment with thalidomide.
Complete response rate
Complete response rates were available for eight of the
thalidomide studies and for the bortezomib (APEX) trial
(Fig. 4). CR required conﬁrmed absence of M-protein
and usually also required fewer than 5% plasma cells in
the bone marrow in a patient and no signs or symptoms
of disease.
The variation in CR rates between the eight thalido-
mide studies was not statistically signiﬁcant (v
2 = 11.9,
7 d.f., P = 0.1) and the mean CR rate was 2% (95%
CI: 1%, 4%). The CR rate with bortezomib treatment
was 8% (95% CI: 6%, 12%). This is higher than was
observed in each of the eight thalidomide studies and is
statistically signiﬁcantly higher than the mean CR for
thalidomide (v
2 = 15.6, 1 d.f., P = 0.0001).
Discussion
In this systematic review in patients with relapsed⁄
refractory multiple myeloma, single-agent bortezomib
was associated with a signiﬁcantly higher response rate.
In keeping with this, the response rate for bortezomib
was also higher than in each of the individual thalido-
mide studies.
The response rate was statistically signiﬁcantly higher
in patients treated with bortezomib than patients treated
with thalidomide regardless of the criteria used to assess
response. When assessed using the simple deﬁnition of
an M-protein reduction of at least 50%, the response
rate observed for bortezomib was 53% compared with a
mean response rate of 32% for thalidomide. In compar-
ison, using the EBMT criteria the response rate for bor-
tezomib was 41% compared with a mean response rate
of 22% for thalidomide. These differences highlight the
need to identify which criteria are used when making
comparisons between therapeutic agents, as stricter cri-
teria are likely to result in more conservative estimates.
Hopefully, as the new response criteria recently proposed
by Durie et al. are adapted more widely, such compari-
sons will be made easier (24).
The slight difference in response rates reported in the
original APEX study and the present analysis are a result
of different analytical approaches. The original APEX
publication used a modiﬁed intent-to-treat analysis based
on patients who received at least one dose of bortezomib
and had measurable disease at baseline (n = 315). In
contrast, in the present study all patients randomised to
receive treatment were evaluated (n = 333). Patients with
no baseline reading were considered to be non-respond-
ers in the present analysis.
The differences in CR rates between bortezomib and
thalidomide are consistent with the overall response rates
reported. The CR rate for bortezomib was 8% compared
with a mean CR rate of 2% for thalidomide. Again, it
should be noted that the CR rate for bortezomib was
higher than in each of the individual thalidomide studies.
Of the 15 thalidomide studies, only six reported data
on progression-free survival. These data appeared to be
inconsistent, probably reﬂecting variation in the fre-
quency and intensity of follow-up between studies. In
one study (22), patients were reported to have low pro-
gression rates with death occurring sooner after progres-
sion than was apparent in other thalidomide studies,
suggesting that the deﬁnition of progression may differ
between the Yakoub-Agha and other studies. Treatment
at relapse was not reported consistently across the stud-
ies and as this treatment could inﬂuence survival, we
have chosen not to report overall survival data.
The results of this analysis are consistent with those
obtained from recent systematic reviews of the efﬁcacy
of single-agent thalidomide in relapsed⁄refractory mul-
tiple myeloma. In the present study, the mean overall
response rate for thalidomide using the most commonly
reported criteria (M-protein reduction of at least 50%)
was 32%. Two recent systematic reviews of single-agent
thalidomide in patients with relapsed⁄refractory multiple
myeloma reported overall response rates of approxi-
mately 28% (17, 18). This is remarkably consistent with
the present analysis, considering that different inclusion
and exclusion criteria were used in each of these
reviews.
One of the limitations of this analysis is that there is
inevitably more variability when combining results from
different studies than if a randomised controlled trial
comparing the two treatments was available. The value
of combining data from multiple studies depends on the
comparability of the studies, both in terms of the
Barlogie et al., 2001
Neben et al., 2002
Mileshkin et al., 2003
Schey et al., 2003
Waage et al., 2004
Hus et al., 2001
Hattori et al., 2003
Richardson et al., 2004
THALIDOMIDE
BORTEZOMIB
0% 5% 10% 15% 20%
Figure 4 Complete response rate in patients with refractory multiple
myeloma treated with either thalidomide or bortezomib.
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being used. Patients receiving bortezomib were very sim-
ilar to those receiving thalidomide in terms of key patient
characteristics. Age, gender, IgG : IgA, disease duration,
and beta-2 microglobulin were well matched between the
two groups. One difference between the patient groups
was that 48% of the bortezomib patients had previously
received thalidomide. Despite the similarity in cardinal
disease descriptors, the patients necessarily came from
different populations, within different treatment infra-
structures and practices. The magnitude of these possible
differences is unknown.
A comparison of bortezomib in combination with dexa-
methasone compared with thalidomide in combination
with dexamethasone is not yet possible. The addition of
corticosteroids does improve the response rate associated
with thalidomide (13–15). Similarly, the evidence to date
suggests an additive or synergistic effect of bortezomib
with dexamethasone in relapsed⁄refractory patients (12).
The synergistic effect of bortezomib with dexamethasone
has also been observed in patients who have not respon-
ded to bortezomib monotherapy (10, 11).
In conclusion, bortezomib was associated with a signi-
ﬁcantly higher response rate than thalidomide in patients
with relapsed⁄refractory multiple myeloma. Comparisons
of thalidomide and bortezomib in combination with
other agents are warranted.
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